吉西他滨联合顺铂治疗晚期非小细胞肺癌临床研究

目的：观察吉西他滨联合顺铂治疗晚期非小细胞肺癌的疗效及毒副反应。方法：经病理组织学或细胞学证实的43例晚期非小细胞肺癌患者给予吉西他滨1000mg/m2静滴,第1,8,15天,顺铂30mg/m2静滴,第1－3天,28天为一周期,或吉西他滨1200mg/m2静滴,第1,8天,顺铂30mg/m2静滴,第1－3天,21天为一周期,结果：全组CR1例,PR20例,SD13例,PD9例,总有效率48．8％,初治病例有效率为62．5％,复治病例为31．6％,两组间差异具有显著性（P＜0．05）,毒副反应以白细胞及血小板下降为常见,但均可耐受,结论：吉西他滨联合顺铂治疗晚期非小细胞肺癌具有较好的疗效。毒性可以耐受。

A clinical study on the combination of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer

Objective　To evaluate the efficacy and toxicity of the combination of gemcitabine and cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods　Forty-three patients with locally advanced (stage ⅢB) or metastatic (stage Ⅳ) NSCLC were enrolled into the study. The patients received gemcitabine 1*!000*!mg／m2 on day 1,8 and 15, and cisplatin 30*!mg／m2 on day 1-3 of the 28-day cycle; or gemcitabine 1*!200*!mg／m2 on day 1 and 8, cisplatin 30*!mg／m2 on day 1-3, administered in 21-day cycle. Results　An objective response was obtained in 48.8％ of patients (one complete and 20 partial responses), whereas 13 patients had stable disease and 9 patients were progressive. The response rate was 62.5％ in patients with no prior chemotherapy, and the response rate of 31.6％ was achieved in patients who had been given prior treatment. Significant difference existed between the two groups (P＜0.05). The main toxicities were leukopenia and thrombocytopenia. Conclusion　The combination of gemcitabine and cisplatin is a feasible, well-tolerated, and active scheme in the treatment of advanced NSCLC.